NEW YORK (TheStreet) -- Shares of Rockwell Medical are up 5.46% to $11.40 after the FDA approved the company's drug Triferic, which is used for treating iron loss in chronic kidney disease patients on dialysis, Reuters reports. Triferic is a unique iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron losses that occur during their dialysis treatment, Rockwell Medical noted. "We see Triferic as a paradigm shift in the treatment of anemia. Importantly, Triferic is the first product that can safely allow dialysis patients to maintain target hemoglobin without the need for IV iron," Chief Medical Officer of Rockwell Medical Raymond Pratt said. Exclusive Report: Jim Cramer's Best Stocks for 2015 STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. "We view today's FDA decision as a major development both for Rockwell and for the entire hemodialysis patient population who now have a significantly better treatment option for addressing their iron losses. We are highly confident in executing a successful commercial launch and penetrating the market," CEO Robert Chioini added. Separately, TheStreet Ratings team rates ROCKWELL MEDICAL INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation: "We rate ROCKWELL MEDICAL INC (RMTI) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself." Highlights from the analysis by TheStreet Ratings Team goes as follows: The gross profit margin for ROCKWELL MEDICAL INC is rather low; currently it is at 18.42%. Regardless of RMTI's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, RMTI's net profit margin of -28.87% significantly underperformed when compared to the industry average. RMTI has underperformed the S&P 500 Index, declining 9.61% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time. ROCKWELL MEDICAL INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, ROCKWELL MEDICAL INC continued to lose money by earning -$1.65 versus -$2.64 in the prior year. This year, the market expects an improvement in earnings (-$0.46 versus -$1.65). The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 70.0% when compared to the same quarter one year prior, rising from -$13.21 million to -$3.97 million. Net operating cash flow has significantly increased by 103.24% to $0.31 million when compared to the same quarter last year. In addition, ROCKWELL MEDICAL INC has also vastly surpassed the industry average cash flow growth rate of -18.13%. You can view the full analysis from the report here: RMTI Ratings Report STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Click to view a price quote on RMTI. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1JtnjrT
No comments:
Post a Comment